Novartis AG
SIP MODULATOR IMMEDIATE RELEASE DOSAGE REGIMEN
Last updated:
Abstract:
The present invention relates to siponimod (BAF312) for use in the treatment of an autoimmune disease, wherein an immediate release dosage form is administered once daily to a patient as maintenance regimen and wherein the patient has experienced a specific titration regimen with siponimod beforehand.
Status:
Application
Type:
Utility
Filling date:
2 Jun 2020
Issue date:
20 Jan 2022